不只瞄准海外!国内药企BD兴起背后:交易规模尚小,有望持续活跃

时代周报
Jan 07

海外BD热潮尚未褪去,国内药企间BD合作开始兴起。1月5日,亿帆医药(002019.SZ)发布公告称,全资子公司亿帆制药与尚德药缘签订《独家协议》,约定尚德药缘有偿将其自主开发的标的产品药物活性成分为二甲胺基含笑内酯富马酸盐一水合物在合作区域、合作领域范围内授予亿帆制药可分许可的、不可撤销的独占性的权利和许可等。亿帆制药需支付1亿元首付款、1亿元基石投资款或5000万元里程碑付款,并根据净销售额...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10